Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 111,680

Document Document Title
WO/2016/103450A1
The present invention addresses the problem of providing an inhibitor which has excellent inhibitory activity on a p21-activated kinase. The present invention, which has solved the above-mentioned problem, is a p21-activated kinase 1 inh...  
WO/2016/103262A2
The present invention provides solid crystalline forms of apomorphine free base or a hydrate, solvate, or co-crystals thereof. Such crystalline forms may be advantageous over amorphous forms of apomorphine, e.g., amorphous salt forms suc...  
WO/2016/101553A1
The present invention relates to a PI3K kinase inhibitor, comprising a compound of a formula I or pharmaceutically acceptable salts, solvate, ester, acid, metabolite, or a prodrug thereof, Y, W, Z, R1, R2, R3, and R4 being defined in the...  
WO/2016/104434A1
To provide a heterocyclic compound having antagonistic activity on NMDA receptors having the NR2B subunit, and which is useful as an agent for treating or preventing major depression, bipolar disorder, migraine, pain, symptoms peripheral...  
WO/2016/103133A1
The invention relates to novel soothing compositions for animals, particularly for cats. It specifically relates to soothing compositions for non-human mammals, comprising between 1% and 50% w/w of at least one fatty acid comprising betw...  
WO/2016/101898A1
The present invention relates to 3-[(benzo[d][1,3]dioxolane-4-yl)-oxy]-3-arylaniline type compounds of Formula I or pharmaceutical acceptable salts thereof and applications thereof. The compound may be used to prepare antidepressants.  
WO/2016/106284A2
The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and ...  
WO/2016/102463A1
The invention relates to a product or pharmaceutical composition comprising remifentanil and propofol, or the pharmaceutically acceptable salts thereof, as a combined preparation for simultaneous use in inducing and maintaining general a...  
WO/2016/106133A1
Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.  
WO/2016/103956A1
The purpose of the present invention is to provide a ropinirole-containing preparation for transdermal administration and a pramipexole-containing preparation for transdermal administration, which have good extended release properties. T...  
WO/2016/101969A1
The present inventions relates to a solid pharmaceutical dosage form comprising Levodopa/Entacapone/Carbidopa, or pharmaceutically acceptable salts or hydrates thereof, characterized in that the active agents are stabilized with the use ...  
WO/2016/103223A1
In one aspect, the invention presents a method of treating Friedreich's ataxia (FRDA) by administering a therapeutically effective amount of an Src inhibitor.  
WO/2016/101432A1
Disclosed in the present invention is a crystal form I of Canagliflozin, and an X-ray powder diffraction spectrum of the crystal form I has characteristic diffraction peaks when 2θ is at the positions of 4.4 ± 0.2°, 8.4 ± 0.2°, 16.8...  
WO/2016/103260A1
The present invention relates to complexes of nocardamine (desferrioxamine E) with at least one metal, specifically with Zn2+ or Ga3+ or silver or gold or any combinations thereof. The invention further provides procedures for the prepar...  
WO/2016/102664A1
The present invention provides for a double stranded RNA comprising a first RNA sequence and a second RNA sequence wherein the first and second RNA sequence are substantially complementary, wherein the first RNA sequence has a sequence l...  
WO/2016/101807A1
A solid pharmaceutical composition comprising topiramate and preparation method therefor. The pharmaceutical composition comprises: topiramate, cellulose derivatives, lipids and optional excipients, where the weight ratio of topiramate t...  
WO/2016/101118A1
An amidoethyl azole compounds are provided as antagonists of orexin receptors. The compounds may be used for treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.  
WO/2016/095650A1
Disclosed are an A-type polymorphic substance of yonkenafil hydrochloride, a preparation method therefor, and a composition and use thereof. A powder diffraction pattern of the A-type polymorphic substance of yonkenafil hydrochloride com...  
WO/2016/097004A1
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to here...  
WO/2016/095778A1
A method for treatment and prevention of air pollution-related diseases, especially diseases related to atmospheric PM2.5 in subjects. The method comprises administering an effective amount of a polyunsaturated fatty acid and vitamin E t...  
WO/2016/100281A1
The present invention relates to indole and azaindole compounds of formula (I), and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.  
WO/2016/095037A1
Methods for treatment and diagnosis of neurological disorders such as autism and autism spectrum disorder are disclosed. Also disclosed are modulators of alternative splicing regulators SRRM4 and/or SRRM3 for treating neurological disord...  
WO/2016/098119A1
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of ...  
WO/2016/100579A1
Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa -1,4-dienyl)butanamide and methods of using such compositions for treating or suppre...  
WO/2016/100801A1
The invention provides therapeutic compositions containing ground seed of Aframomum meleguata or an extract thereof, and methods for using such compositions to reduce platelet aggregation and treat medical disorders in a patient, such as...  
WO/2016/098005A1
The present invention is related to amino thiazole derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleoti...  
WO/2016/097351A1
The present invention relates to compounds of Formula (I) wherein R1 and R2 are independently selected from 19F and 18F having selective binding for MAO-B as compared with MAO-A. The invention also provides radioactive versions of these ...  
WO/2016/099055A2
The present invention relates to a composition containing a mixed extract of mulberry and Poria cocos bark as an effective ingredient for preventing, improving, or treating neurodegenerative disorders, and to a use thereof. The mixed ext...  
WO/2016/096720A1
A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.  
WO/2016/095702A1
The present invention belongs to the field of medicine and the chemical industry, and in particular relates to a variety of scutellarin aglycone crystal forms and a preparation method thereof. The present invention also relates to a use ...  
WO/2016/100184A1
The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7- nAChR, and methods of preparing these compoun...  
WO/2016/099056A2
The present invention relates to a pharmaceutical composition containing a Poria cocos bark extract as an effective ingredient for preventing or treating neurodegenerative disorders, and to a food composition for preventing or improving ...  
WO/2016/099393A1
A compound of formula I, for use in pain therapy and a pharmaceutical composition comprising said compound.  
WO/2016/096979A1
The present invention relates to 2,3,4,5-tetrahydropyridin-6-amine and 3,4- dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase having the structure shown in Formula (I), wherein the radicals are as defined in the specificati...  
WO/2016/097339A1
The present invention relates to compounds having selective binding for MAO-B as compared with MAO-A. The invention also provides radioactive versions of these compounds, and precursor compounds for the synthesis of these radioactive com...  
WO/2016/099394A1
A compound of formula I, For use in pain therapy and a pharmaceutical composition comprising said compound.  
WO/2016/096709A1
The present invention relates to novel heterocyclic derivatives having general formula (I) and their therapeutic use for diseases such as cancer, inflammation, pain, autoimmune diseases or neurodegenerative diseases like Alzheimer's or P...  
WO/2016/097144A1
Compound of formula (I) wherein R1 is heteroaryl either unsubstituted or substituted by methyl, ethyl, halo or =O; and R2 is H, methyl or ethyl; and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders...  
WO/2016/100708A1
A transdermal drug delivery device includes a backing and an adhesive composition disposed on the backing. The adhesive composition includes a copolymer having at least 50 percent by weight C4 to C10 alkyl acrylate units, based on the to...  
WO/2016/095204A1
The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurologic...  
WO/2016/096127A1
The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to methyl-1H-pyrazole alkylamine compounds having this pharmacological ...  
WO/2016/097345A1
The present invention relates to compounds having selective binding for MAO-B as compared with MAO-A. The invention also provides radioactive versions of these compounds, and precursor compounds for the synthesis of these radioactive com...  
WO/2016/100576A1
The invention relates to methods of separating Trolox isomers (R)-Trolox and (S)-Trolox, comprising: (a) contacting a mixture of (R) and (S)-Trolox with a resolving agent selected from the group consisting of (1S,2S)-(+)-Pseudoephedrine,...  
WO/2016/100515A1
The invention generally relates to substituted benzothiophenyl, substituted benzothiazolyl, substituted indolyl and substituted benzoimidazolyl compounds and, more particularly, to a compound represented by Structural Formula I: or a pha...  
WO/2016/095205A1
Disclosed are heteroaryl compounds and compositions which are antagonists of orexin receptors. Also disclosed are uses of the compounds and compositions in the potential treatment or prevention of neurological and psychiatric disorders a...  
WO/2016/097355A1
The present invention relates to compounds having selective binding for MAO-B as compared with MAO-A. The invention also provides radioactive versions of these compounds, and precursor compounds for the synthesis of these radioactive com...  
WO/2016/094850A1
The invention includes a composition comprising an astrocyte comprising aligned and elongated astrocyte processes resulting from ex vivo machine-driven, physical stretching of the astrocyte maintained in culture, as well as a method of m...  
WO/2016/091079A1
The present invention relates to donepezil derivatives of general formula (I) or pharmaceutically acceptable salts thereof, wherein R is described in the specification; preparation methods therefor and compositions comprising an effectiv...  
WO/2016/090495A1
The present invention is related to a compound that includes (a) α-L-iduronidase (IDUA), a fragment, or analog thereof and (b) a dendrimeric targeting moiety, for example, a dendrimeric targeting moiety including Angiopep-2. In certain ...  
WO/2016/092042A1
The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2- ([Z]- propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically...  

Matches 51 - 100 out of 111,680